Welcome to our dedicated page for Climb Bio SEC filings (Ticker: CLYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Climb Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Climb Bio's regulatory disclosures and financial reporting.
Climb Bio, Inc. reported that stockholders approved an amendment to its 2021 Equity Incentive Plan at the 2026 annual meeting. The change updates the automatic annual share increase so it is based on both common shares and any outstanding pre-funded warrants starting with future evergreen calculations.
The underlying plan authorizes up to 5,216,105 shares for equity awards, combining new and returning shares, and permits annual increases of up to 5% of the applicable share base. Stockholders also elected directors and approved other proposals by wide margins, and the amended plan was filed as an exhibit.
Climb Bio, Inc. reported translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, its anti-APRIL monoclonal antibody. The data come from a Phase 1 study in Australia and a parallel Phase 1 study run by partner Beijing Mabworks Biotech in China.
Based on the safety profile observed so far and supportive preclinical results, Climb Bio plans to continue advancing CLYM116 in clinical development. Mabworks expects to begin dosing IgA nephropathy (IgAN) patients in the Phase 2 portion of its ongoing study in the third quarter of 2026, marking a move toward testing the drug in its target indication.
Climb Bio, Inc. is registering the resale of up to 11,587,000 shares of its common stock via a prospectus dated May 29, 2026, to permit selling stockholders to resell shares acquired in a recent private placement and related transactions. The registered shares consist of 9,481,000 outstanding shares held by the selling stockholders and 2,106,000 shares issuable upon exercise of prefunded warrants held by one selling stockholder.
The company states it will not receive any proceeds from sales by the selling stockholders; however, if the prefunded warrants are exercised for cash, Climb Bio will receive the exercise price. Shares outstanding were 57,263,023 as of May 14, 2026.
Climb Bio, Inc. reported a net loss of $13.7 million for the quarter ended March 31, 2026, narrower than the $20.8 million loss a year earlier, as research and development spending declined to $9.4 million from $17.3 million.
The company ended the quarter with $146.3 million in cash, cash equivalents and marketable securities, which it currently expects to fund operations into 2028. In April 2026, Climb Bio raised about $110 million in a private placement to further support its immune‑mediated disease pipeline, including lead programs budoprutug and CLYM116.
Climb Bio, Inc. reported first quarter 2026 results, continued progress across its two lead programs, and strengthened its balance sheet. The company recorded a net loss of $13.7 million for the three months ended March 31, 2026, compared with $20.8 million a year earlier, as research and development spending declined.
Cash, cash equivalents and marketable securities totaled $146.3 million as of March 31, 2026, and management expects this to fund operations into 2028, excluding proceeds from a recently completed private placement. On April 29, 2026, Climb Bio closed a $110 million private financing led by healthcare investors.
Clinically, the anti‑CD19 antibody budoprutug showed robust B‑cell depletion with its subcutaneous formulation in healthy volunteers, supporting further development in autoimmune diseases. Multiple Phase 1b/2a and Phase 2 trials in primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus are enrolling, with several data readouts anticipated in 2026.
Climb Bio, Inc. filed a current report describing an R&D spotlight focused on budoprutug, its anti-CD19 monoclonal antibody for immune‑mediated diseases. The company highlights robust B‑cell depletion with a subcutaneous formulation in healthy volunteers and ongoing trials in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE).
Budoprutug has received FDA Orphan Drug and Fast Track designations for pMN and showed durable B‑cell depletion, anti‑PLA2R antibody negativity in evaluable patients, and clinical remissions in a small Phase 1b pMN study. Climb Bio also notes its second program, CLYM116, an anti‑APRIL antibody for IgA nephropathy, and states it is well‑resourced with cash runway anticipated into 2028, supporting multiple planned 2026 data readouts across budoprutug and CLYM116.
Climb Bio, Inc. reported that investment entities affiliated with RA Capital acquired pre-funded warrants linked to its common stock. The filing shows an indirect grant of 2,106,000 Pre-Funded Warrants, each exercisable for one share of common stock.
The warrants were acquired at $9.4999 per warrant and have a nominal exercise price of $0.0001 per share. They are exercisable immediately and have no expiration date, but their exercise is limited so that RA Capital–affiliated holders and related groups cannot beneficially own more than 33.0% of Climb Bio’s outstanding common stock after exercise. Following this grant, the reporting RA Capital entities show 22,546,000 pre-funded warrants beneficially owned, subject to footnoted pecuniary-interest and beneficial-ownership disclaimers.
RA Capital Management and affiliates report a significant position in Climb Bio, Inc., beneficially owning 22,631,401 shares of common stock, or 33.0% of the class. The stake includes common shares, stock options and pre-funded warrants that are exercisable within 60 days, subject to ownership limits.
The filing details an April 2026 private placement in which Climb Bio issued 9,481,000 common shares at $9.50 per share and 2,106,000 pre-funded warrants at $9.4999 each. RA Capital’s fund purchased all 2,106,000 pre-funded warrants for $20,006,789.40, funded from its working capital.
The pre-funded warrants are exercisable at $0.0001 per share and do not expire, but a 33.0% beneficial ownership blocker restricts further exercise above that threshold. Climb Bio agreed to register for resale both the private placement shares and the warrant shares under a registration rights agreement that includes filing deadlines, effectiveness requirements and potential liquidated damages.
Climb Bio, Inc. entered into a securities purchase agreement for a private placement of its common equity. The company is selling 9,481,000 common shares at $9.50 per share and pre-funded warrants to purchase 2,106,000 shares at $9.4999 per warrant, for aggregate gross proceeds of about $110.0 million before fees.
Each pre-funded warrant is immediately exercisable at $0.0001 per share, subject to beneficial ownership limits generally at 4.99% or 9.99%, and up to 33.0% for RA Capital, with an overall cap of 19.99% for other holders. Climb Bio also agreed to register the resale of the new shares and warrant shares within 45 days after closing, and states that existing cash plus anticipated net proceeds are expected to support continued execution toward late-stage development of its immune-mediated disease pipeline.